Use of 111In-Capromab Pendetide Immunoscintigraphy to Image Localized Prostate Cancer Foci Within the Prostate Gland

Journal of Urology

Volumn 182, Issue 3, 2009, Pages 938-948

  Mouraviev, Vladimir ^a   Madden, John F ^b   Broadwater, Gloria ^b   Mayes, Janice M ^b   Burchette, James L ^b   Schneider, Frank ^b   Smith, Jill ^a   Tsivian, Matvey ^a   Wong, Terence ^b   Polascik, Thomas J ^a  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

capromab pendetide; emission computed; prostate; prostatic neoplasms; single photon; tomography; x ray computed

Indexed keywords

CAPROMAB PENDETIDE IN 111; PROSTATE SPECIFIC MEMBRANE ANTIGEN; CAPROMAB PENDETIDE; DIAGNOSTIC AGENT; INDIUM; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DRUG ACCUMULATION; HISTOPATHOLOGY; HUMAN; IMAGE RECONSTRUCTION; IMMUNOHISTOCHEMISTRY; IMMUNOSCINTIGRAPHY; INTERMETHOD COMPARISON; MALE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SINGLE BLIND PROCEDURE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VALIDATION STUDY; COMPUTER ASSISTED TOMOGRAPHY; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; PROSTATE; PROSTATE TUMOR; SCINTISCANNING;

AGED; ANTIBODIES, MONOCLONAL; HUMANS; INDIUM RADIOISOTOPES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 68149156403     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.05.047     Document Type: Article

References (32)

1. Sodee D.B., Ellis R.J., Samuels M.A., et al. Prostate cancer and prostate bed SPECT imaging with ProstaScint: semiquantitative correlation with prostatic biopsy results. Prostate 37 (1998) 140
2. Raj G.V., Partin A.W., and Polascik T.J. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer 94 (2002) 987
3. Polascik T.J., Manyak M.J., Haseman M.K., et al. Comparison of clinical staging algorithms and 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients. Cancer 85 (1999) 1586
4. Manyak M.J., Hinkle G.H., Olsen J.O., et al. Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer. Urology 54 (1999) 1058
5. Ellis R.J., Kim E.Y., Conant R., et al. Radioimmunoguided imaging of prostate cancer foci with histopathological correlation. Int J Radiat Oncol Biol Phys 49 (2001) 1281
6. Polascik T.J., Mayes J.M., Sun L., et al. Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. Prostate 68 (2008) 1380
7. Polascik T.J., and Mouraviev V. Focal therapy for prostate cancer. Curr Opin Urol 18 (2008) 269
8. Ahmed H.U., and Emberton M. Active surveillance and radical therapy in prostate cancer: can focal therapy offer the middle way?. World J Urol 26 (2008) 457
9. Koontz B.F., Mouraviev V., Johnson J.L., et al. Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 71 (2008) 358
10. Wong T.Z., Turkington T.G., Polascik T.J., et al. ProstaScint (capromab pendetide) imaging using hybrid gamma camera-CT technology. AJR Am J Roentgenol 184 (2005) 676
11. Ross J.S., Sheehan C.E., Fisher H.A., et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 9 (2003) 6357
12. D'Amico A.V., Moul J., Carroll P.R., et al. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 21 (2003) 2163
13. Ellis R.J., and Kaminsky D.A. Fused radioimmunoscintigraphy for treatment planning. Rev Urol, suppl. 1 (2006) S11
14. Sodee D.B., Sodee A.E., and Bakale G. Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Semin Nucl Med 37 (2007) 17
15. Nagda S.N., Mohideen N., Lo S.S., et al. Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 67 (2007) 834
16. Hollenbeck B.K., Bassily N., Wei J.T., et al. Whole mounted radical prostatectomy specimens do not increase detection of adverse pathological features. J Urol 164 (2000) 1583
17. Desai A., Wu H., Sun L., et al. Complete embedding and close step-sectioning of radical prostatectomy specimens both increase detection of extra-prostatic extension, and correlate with increased disease-free survival by stage of prostate cancer patients. Prostate Cancer Prostatic Dis 5 (2002) 212
18. Ellis R.J., Zhou E.H., Fu P., et al. Single photon emission computerized tomography with capromab pendetide plus computerized tomography image set co-registration independently predicts biochemical failure. J Urol 179 (2008) 1768
19. Keane T.E., Rosner I.L., Wingo M.S., et al. The emergence of radioimmunoscintigraphy for prostate cancer. Rev Urol, suppl. 1 (2006) S20
20. Sodee D.B., Malguria N., Faulhaber P., et al. Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers. Urology 56 (2000) 988
21. Proano J.M., Sodee D.B., Resnick M.I., et al. The impact of a negative (111)indium-capromab pendetide scan before salvage radiotherapy. J Urol 175 (2006) 1668
22. Thomas C.T., Bradshaw P.T., Pollock B.H., et al. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol 21 (2003) 1715
23. Kahn D., Williams R.D., Manyak M.J., et al., The ProstaScint Study Group. 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. J Urol 159 (1998) 2041
24. Wright G.L., Haley C., Beckett M.L., et al. Expression of prostate-specific membrane antigen in normal, benign and malignant prostate tissues. Urol Oncol 1 (1995) 18
25. Silver D.A., Pellicer I., Fair W.R., et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3 (1997) 81
26. Perner S., Hofer M.D., Kim R., et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 38 (2007) 696
27. Mannweiler S., Amersdorfer P., Trajanoski S., et al. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res 15 (2008) 167
28. Holmes E.H. PSMA specific antibodies and their diagnostic and therapeutic use. Expert Opin Investig Drugs 10 (2001) 511
29. Sweat S.D., Pacelli A., Murphy G.P., et al. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 52 (1998) 637
30. Bostwick D.G., Pacelli A., Blute M., et al. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 82 (1998) 2256
31. Wang W., Tavora F., Sharma R., et al. PSMA expression in Schwannoma: a potential clinical mimicker of metastatic prostate carcinoma. Urol Oncol (2008)
32. Mhawech-Fauceglia P., Smiraglia D.J., Bshara W., et al. Prostate-specific membrane antigen expression is a potential prognostic marker in endometrial adenocarcinoma. Cancer Epidemiol Biomarkers Prev 17 (2008) 571